← All organizations
Highest phase reached
Phase 2
First clinical trial
Jul 1, 2017First marketed drug
Aug 8, 2018First NDA
Aug 8, 2018Last known activity
Feb 28, 2025
Timeline
2010s
- Jan 1, 2010
60 Degrees Pharmaceuticals LLC— Founded
- Aug 8, 2018
tafenoquine succinate— NDA Organization
- Aug 8, 2018
tafenoquine succinate— NDA Secondary Org
Drugs by trial phase (3 distinct, 6 trials)
Phase 2 (3 own, 0 via acquisition)
Indications
Approved for
Marketed drugs (1)
Recent trials (6)
- NCT06478641Lead sponsorN/A—
- NCT06656351Lead sponsorPhase 2Feb 28, 2025
- NCT06207370Lead sponsorPhase 2Jun 17, 2024
- NCT04533347Lead sponsorPhase 2Oct 31, 2020
- NCT03320174Lead sponsorPhase 2Oct 5, 2017
- NCT02569827CollaboratorPhase 1/Phase 2Jul 1, 2017
Details
- Founded
- Washington D.C., US Jan 1, 2010
- First NDA
- Aug 8, 2018
- Last known activity
- Feb 28, 2025
Designations held
- Orphan drug
- Priority review
- Breakthrough therapy